PGx testing with education improved understanding and perceived utility compared to test results alone in a randomized trial.

This single-center randomized control trial evaluated the impact of pharmacogenomic (PGx) testing strategies on patient comprehension. The study population consisted of pregnant individuals and families or guardians of children with a chronic health condition aged 0-16. The sample size was not reported. Participants were randomized to receive either PGx testing with return of results and an educational video about PGx testing, or PGx test results alone.

The primary outcome measured was patients' understanding and perceived utility of PGx testing. Secondary outcomes included participants' knowledge and attitudes regarding PGx testing at baseline and after receiving results. However, the main results section of the provided evidence did not contain specific numerical data, percentages, or p-values to report on these outcomes.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and overall tolerability, were not reported. The follow-up duration was not reported. Funding or conflicts of interest were not reported. Specific limitations regarding the study design or population were not listed in the provided input.

Practice relevance was not reported. Given the lack of numerical results and safety data, the clinical utility of adding an educational video to PGx testing results remains uncertain based on this specific evidence summary.